



22 June 2020

OMEGA DIAGNOSTICS GROUP PLC
(“Omega” or the “Company” or the “Group”)

Investor presentation

Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and COVID-19 testing, announces that a Company presentation delivered by Colin King, Chief Executive, and Kieron Harbinson, Group Finance Director, to update shareholders following the recent fundraising announcement, is now available to view on the Company’s website: <http://www.omegadiagnostics.com/Investor-Relations/Corporate-Information>

No new price-sensitive information is disclosed as part of the presentation. Within the presentation the Company provides indicative guidance on timelines for product evaluations, product supply, potential timing for first commercial sales and targeted production volumes. These timelines are for guidance purposes only and there is no guarantee that these will be met. The Company expects to keep shareholders updated regularly on progress in achieving these future milestones.

Contacts:

Omega Diagnostics Group PLC

Bill Rhodes, Interim Non-Executive Chairman
Colin King, Chief Executive
Kieron Harbinson, Group Finance Director

Tel: 01259 763 030
www.omegadiagnostics.com

finnCap Ltd

Geoff Nash/Hannah Boros (Corporate Finance)
Camille Gochez (ECM)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or omega@walbrookpr.com
Mob: 07980 541 893
Mob: 07584 391 303